FDA Approves Dupilumab for Allergic Fungal Rhinosinusitis: Improved Sinus Opacification in Patients

Executive Brief

News Report

The News: FDA approves dupilumab for allergic fungal rhinosinusitis in patients aged 6 and older.
Clinical Win: Dupilumab shows significant efficacy in improving sinus opacification and reducing surgery needs.
Target Specialty: Otolaryngology

Key Data at a Glance

Approval Date: February 2026
Patient Population: Patients aged 6 years and older with AFRS
Trial Duration: 52 weeks

The FDA has approved dupilumab (Dupixent) for the treatment of allergic fungal rhinosinusitis (AFRS) in patients aged 6 years and older with a history of sino-nasal surgery. This approval marks a significant advancement in the management of a condition that can lead to severe complications if left untreated.

Clinical Context

Allergic fungal rhinosinusitis (AFRS) is a chronic inflammatory condition of the sinuses characterized by an allergic response to fungi. It affects approximately 8% of individuals with chronic sinusitis and is particularly prevalent in warm, humid climates. The condition typically manifests in adolescents and young adults, leading to symptoms such as nasal congestion, facial pain, and reduced sense of smell. Untreated AFRS can result in serious complications, including sinus expansion, bone erosion, and potential spread to the eyes or brain, which can lead to vision problems and facial deformities. Current treatment options often include systemic corticosteroids and surgical interventions, but these can be inadequate for many patients. Dupilumab, a monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling, has previously been established as an effective treatment for various allergic conditions, making its new indication for AFRS particularly relevant.

Key Findings

The dupilumab clinical trial demonstrated that dupilumab reduced sinus opacification significantly compared to placebo, as measured by the Lund-Mackay CT score, over a 52-week period (exact percentage improvement not specified) [7].

The trial enrolled 300 adult and pediatric participants aged 6 years and older with a history of sino-nasal surgery and diagnosed with AFRS [7].

Event rates: Dupilumab significantly reduced the need for systemic corticosteroids and sinus surgeries compared to placebo, showcasing its effectiveness in managing this complex condition [7].

The primary endpoint was the change in sinus opacification as measured by CT scan scores [7].

What This Means for Clinical Practice

Dupilumab is now indicated for patients aged 6 years and older with allergic fungal rhinosinusitis who have a history of sino-nasal surgery. This new approval provides an additional therapeutic option for clinicians managing patients with AFRS, particularly those who have not responded adequately to traditional treatments. The data supporting dupilumab's efficacy in improving sinus opacification and reducing the need for surgery could lead to better management strategies for this challenging condition. Clinicians should consider evaluating their patients for AFRS and discussing the potential benefits of dupilumab, especially in those with severe symptoms or recurrent disease. The integration of dupilumab into treatment protocols may also help reduce the burden of surgery and systemic corticosteroid use, ultimately improving patient outcomes and quality of life.

Clinical Perspective

Workflow: The approval of dupilumab allows clinicians to offer a targeted therapy for patients with AFRS, potentially reducing reliance on surgery.

Economics: By decreasing the need for surgical interventions, dupilumab may lower healthcare costs associated with managing AFRS.

Patient Outcomes: Improved management of AFRS with dupilumab can lead to enhanced quality of life and reduced complications for patients.

Editorial Team, Otolaryngology

References

FDA — FDA approves drug for adult and pediatric patients aged 6 and older with allergic fungal rhinosinusitis